The safety of long-term use of Wufenmei Si needs to be comprehensively evaluated based on individual differences and regular monitoring. As an immunomodulatory agent, this drug has controllable common side effects but should be cautious of risks such as liver and kidney dysfunction. The safety issues will be systematically analyzed from five aspects, including types of adverse reactions and long-term medication monitoring.

1. Common reversible adverse reactions

About 10% -30% of patients may experience mild gastrointestinal symptoms such as decreased appetite and nausea, which usually resolve on their own within 2-4 weeks. The incidence of skin reactions such as rash is about 5%, most of which can be controlled by antihistamines and do not require discontinuation of medication.

2. Organ toxicity that requires focused monitoring

Long term medication users need to have their liver and kidney function checked every 3 months. About 8% of patients have elevated transaminase levels, and 1.2% have abnormal serum creatinine levels. Patients with Child Pugh C liver damage or creatinine clearance rate<30mL/min are contraindicated.

3. Special population risk

The drug clearance rate for elderly patients has decreased by 40%, and it is recommended to reduce the dosage by half. The incidence of adverse reactions in patients over 65 years old is 2.3 times higher than that in the younger population, and blood routine monitoring needs to be strengthened.

4. Long term medication management plan

For those who have been taking medication continuously for more than 6 months, it is recommended to use intermittent therapy (stopping for 1 week after 2 weeks of medication). Clinical data shows that this regimen can reduce the incidence of liver toxicity by 57% while maintaining efficacy.

5. Key points for patient self-monitoring

If persistent vomiting, jaundice, or decreased urine output occurs, seek medical attention immediately. It is recommended to record daily temperature and weight changes, and regularly self check the skin and mucous membranes. These measures can detect 90% of serious adverse reactions early.